Eating Disorders: A Pharmacological Deep Dive into Anorexia, Bulimia, and Binge‑Eating

Eating disorders are among the most lethal psychiatric illnesses, with mortality rates rivaling those of cancer and cardiovascular disease. A 2021 national survey found that 1.5% of adults meet criteria for anorexia nervosa, 4% for bulimia nervosa, and 3% for binge‑eating disorder—yet many cases remain undiagnosed. In clinical practice, a 28‑year‑old woman presents to the emergency department after a 3‑month history of extreme weight loss, self‑induced vomiting, and a body mass index of 15.2, underscoring the urgent need for evidence‑based pharmacotherapy. This article reviews the pharmacological landscape of anorexia, bulimia, and binge‑eating disorders, integrating pathophysiology, drug mechanisms, dosing, safety, and exam‑ready insights.

Introduction and Background

Eating disorders (EDs) trace their clinical description back to the late 19th century, when Dr. William Gull first described “anorexia nervosa” as a “psychical disease of the appetite.” Over the past eight decades, epidemiologic studies have revealed a complex interplay of genetic, neurobiological, and sociocultural factors. Contemporary meta‑analyses estimate lifetime prevalence of anorexia nervosa at 0.3–0.5% in females and 0.1% in males, with bulimia nervosa affecting 1–3% of women and 0.5–1% of men, and binge‑eating disorder impacting 2–4% of adults worldwide.

From a pharmacologic standpoint, EDs are characterized by dysregulation of serotonergic, dopaminergic, glutamatergic, and orexigenic pathways. Serotonin (5‑HT) transporter polymorphisms, reduced 5‑HT2C receptor density, and altered dopamine D2/D3 receptor availability have all been implicated in the binge‑eating and bulimic phenotypes. In anorexia, the neuroendocrine milieu shifts toward a catabolic state, with elevated cortisol, reduced leptin, and increased ghrelin, creating a self‑reinforcing cycle of restrictive eating and metabolic adaptation. These neurochemical insights have guided the therapeutic use of selective serotonin reuptake inhibitors (SSRIs), serotonin‑norepinephrine reuptake inhibitors (SNRIs), topiramate, and lisdexamfetamine, among others.

Despite advances, no single pharmacologic agent has achieved universal approval for anorexia nervosa, reflecting the disorder’s heterogeneous presentation and the challenges of conducting placebo‑controlled trials in a population with life‑threatening malnutrition. Bulimia nervosa and binge‑eating disorder, however, have benefited from FDA approvals of fluoxetine and lisdexamfetamine, respectively, marking a turning point in the pharmacologic management of these conditions. Understanding the mechanistic underpinnings of these drugs, along with their pharmacokinetic (PK) and pharmacodynamic (PD) profiles, remains essential for optimizing therapeutic outcomes.

Mechanism of Action

Selective Serotonin Reuptake Inhibitors (SSRIs)

SSRIs, such as fluoxetine and sertraline, competitively inhibit the serotonin transporter (SERT) located on presynaptic serotonergic neurons. By blocking reuptake, they increase extracellular 5‑HT concentrations, which in turn activate postsynaptic 5‑HT1A and 5‑HT2C receptors. Activation of 5‑HT1A autoreceptors reduces firing of serotonergic neurons, while postsynaptic 5‑HT2C activation modulates appetite and impulse control through downstream inhibition of GABAergic interneurons in the hypothalamus and nucleus accumbens. In bulimia nervosa, this serotonergic modulation dampens the urge to binge and the compensatory vomiting response, whereas in binge‑eating disorder, it enhances satiety signaling and reduces compulsive eating episodes.

Serotonin–Norepinephrine Reuptake Inhibitors (SNRIs)

SNRIs, exemplified by venlafaxine, inhibit both SERT and the norepinephrine transporter (NET). The dual blockade elevates synaptic 5‑HT and norepinephrine, amplifying serotonergic tone and augmenting noradrenergic modulation of the locus coeruleus. Enhanced norepinephrine activity improves attention and executive function, which can counteract the impulsivity seen in binge episodes. Additionally, the increased catecholamine signaling dampens the reward circuitry associated with high‑calorie foods, thereby reducing binge frequency.

Antiepileptic Drug Topiramate

Topiramate exerts a multifaceted mechanism: it enhances gamma‑aminobutyric acid (GABA) A receptor activity, inhibits voltage‑gated sodium channels, blocks AMPA/kainate glutamate receptors, and reduces carbonic anhydrase II activity. The net effect is a dampening of neuronal excitability in the amygdala and prefrontal cortex, which are implicated in the emotional dysregulation that precedes binge episodes. Furthermore, topiramate’s influence on leptin and ghrelin pathways promotes satiety and reduces caloric intake, making it effective for binge‑eating disorder and weight management in anorexia nervosa.

Stimulant Lisdexamfetamine

Lisdexamfetamine is a prodrug that is enzymatically converted to dextroamphetamine. Dextroamphetamine increases synaptic dopamine and norepinephrine by reversing the dopamine transporter (DAT) and norepinephrine transporter (NET) and inhibiting monoamine oxidase A (MAO‑A). The resultant surge in dopaminergic tone in the mesolimbic pathway suppresses the reinforcing properties of palatable foods, while heightened noradrenergic activity improves attention and reduces impulsive bingeing. In clinical trials, lisdexamfetamine has demonstrated a dose‑dependent reduction in binge‑episode frequency and a modest weight loss effect in patients with binge‑eating disorder.

Clinical Pharmacology

Understanding the PK/PD characteristics of agents used in eating disorders is critical for dose titration, monitoring for adverse effects, and anticipating drug–drug interactions. The following sections summarize key parameters for the most frequently employed medications.

Fluoxetine’s long half‑life and active metabolite prolong serotonergic effects, providing a steady therapeutic window that tolerates missed doses. Sertraline, with a shorter half‑life, requires strict adherence to maintain adequate 5‑HT levels. Topiramate’s rapid elimination necessitates titration over several weeks to mitigate neurocognitive side effects while achieving therapeutic plasma concentrations. Lisdexamfetamine’s prodrug nature leads to a delayed onset of action, allowing for gradual titration and reduced abuse potential relative to immediate‑release amphetamines.

In terms of dose–response, fluoxetine shows diminishing returns beyond 60 mg/day, whereas sertraline continues to exhibit incremental benefits up to 200 mg/day. Topiramate’s efficacy peaks around 150 mg/day; higher doses produce diminishing gains but increase neurocognitive adverse events. Lisdexamfetamine displays a steep dose–response curve, with 30–60 mg/day producing clinically meaningful reductions in binge frequency, but higher doses raise the risk of cardiovascular side effects.

Therapeutic Applications

Below is a concise overview of FDA‑approved and commonly used off‑label pharmacotherapies for anorexia nervosa, bulimia nervosa, and binge‑eating disorder.

• Fluoxetine (Prozac): FDA‑approved for bulimia nervosa (60 mg/day). Off‑label for binge‑eating disorder (60 mg/day) and anorexia nervosa (20–60 mg/day). Dosing starts at 20 mg/day, titrated weekly by 20 mg increments to a maximum of 60 mg/day.

• Sertraline (Zoloft): Off‑label for bulimia nervosa (50–200 mg/day) and binge‑eating disorder (50–200 mg/day). Initiate at 25 mg/day, increase every 1–2 weeks by 25 mg.

• Topiramate (Topamax): FDA‑approved for seizure disorders; used off‑label for binge‑eating disorder (200 mg/day) and weight management in anorexia nervosa. Start at 25 mg/day, titrate by 25 mg weekly to 200 mg/day.

• Lisdexamfetamine (Vyvanse): FDA‑approved for binge‑eating disorder (30–70 mg/day). Begin at 30 mg/day, increase by 10 mg every 1–2 weeks to a target of 70 mg/day.

• Antipsychotics (Olanzapine, Quetiapine): Off‑label for anorexia nervosa and bulimia nervosa to address mood dysregulation and compulsive behaviors; typical doses 10–20 mg/day for olanzapine, 25–50 mg/day for quetiapine.

• Thyroid Hormone (Levothyroxine): Off‑label for anorexia nervosa with hypothyroidism; doses 50–200 µg/day based on TSH levels.

• Vitamin and Mineral Supplementation: Essential for all EDs; high‑dose iron, vitamin D, calcium, and B‑complex vitamins are routinely prescribed.

Special Populations

1. Pediatrics: Fluoxetine and sertraline are approved for adolescents (12–17 years) with bulimia nervosa; dosing is weight‑based, starting at 0.5 mg/kg/day.

2. Geriatrics: Reduced metabolic clearance necessitates lower starting doses of fluoxetine (10 mg/day) and close monitoring for anticholinergic side effects.

3. Renal Impairment: Topiramate and lisdexamfetamine are primarily renally excreted; dose adjustments are required in creatinine clearance < 30 mL/min.

4. Hepatic Impairment: Fluoxetine and sertraline are metabolized hepatically; caution in Child‑Pugh B/C; consider lower doses.

5. Pregnancy: Fluoxetine is category C; limited data support use of sertraline; caution with topiramate due to teratogenicity (neural tube defects).

Adverse Effects and Safety

Adverse effect profiles vary across agents, necessitating individualized risk–benefit assessment.

Common Side Effects (Incidence)

• Fluoxetine: nausea (12 %), insomnia (8 %), sexual dysfunction (6 %), weight gain (4 %).

• Sertraline: diarrhea (10 %), sexual dysfunction (7 %), weight loss (5 %), dizziness (4 %).

• Topiramate: paresthesia (30 %), cognitive blunting (15 %), dysgeusia (10 %), weight loss (8 %).

• Lisdexamfetamine: decreased appetite (25 %), insomnia (18 %), increased heart rate (12 %), anxiety (8 %).

Serious/Black Box Warnings

• Fluoxetine: increased risk of suicidal ideation in patients < 25 years; serotonin syndrome with MAO inhibitors.

• Sertraline: serotonin syndrome; QT prolongation in high doses.

• Topiramate: risk of metabolic acidosis; potential for acute renal failure; teratogenicity (neural tube defects).

• Lisdexamfetamine: cardiovascular events (hypertension, tachycardia); potential for abuse and dependence.

Drug Interactions

Monitoring Parameters

• Baseline and periodic ECG for QT monitoring (sertraline, topiramate).

• Blood pressure and heart rate for lisdexamfetamine.

• Serum creatinine and eGFR for topiramate and lisdexamfetamine.

• Weight and BMI changes for all agents.

• Serotonin syndrome assessment (e.g., clonus, hyperreflexia).

Contraindications

• Fluoxetine: MAO inhibitor therapy; hypersensitivity to fluoxetine.

• Sertraline: MAO inhibitor therapy; severe hepatic impairment.

• Topiramate: History of kidney stones; severe respiratory failure.

• Lisdexamfetamine: Uncontrolled hypertension; severe cardiovascular disease; history of substance abuse.

Clinical Pearls for Practice

• Start low, go slow. For fluoxetine, begin at 20 mg/day and titrate weekly to avoid serotonin syndrome.

• Use the “Binge‑eating” mnemonic. B‑E‑N‑D: Behavioral therapy, Naltrexone, Dexamethasone, and (in this context) Dextroamphetamine (lisdexamfetamine) can be considered for refractory cases.

• Monitor weight changes closely. A > 5 % weight loss in < 4 weeks on topiramate signals the need to adjust dose.

• Screen for cardiac risk. All stimulants require baseline ECG and BP; avoid in patients with arrhythmias.

• Check renal function before initiating topiramate. If eGFR < 30 mL/min, consider dose reduction or alternative therapy.

• Educate patients on serotonin syndrome. Symptoms include agitation, tremor, and hyperthermia; immediate cessation of serotonergic drugs is essential.

• Consider antipsychotics for mood dysregulation. Olanzapine can be added for patients with comorbid depression or anxiety when SSRIs are inadequate.

Comparison Table

Exam‑Focused Review

USMLE Step 2 CK and NAPLEX frequently probe the pharmacologic management of eating disorders. Below are representative question stems and critical differentiators.

• Question Stem: A 22‑year‑old female with bulimia nervosa presents for medication initiation. Which agent is FDA‑approved for this indication?
  Answer: Fluoxetine (60 mg/day). Rationale: Only SSRI with proven efficacy and FDA approval for bulimia.

• Question Stem: A patient with binge‑eating disorder on topiramate complains of cognitive slowing. What is the most appropriate next step?
  Answer: Reduce dose or discontinue. Rationale: Cognitive blunting is dose‑dependent; titrate carefully.

• Question Stem: Which medication carries a teratogenic risk of neural tube defects and should be avoided in pregnancy?
  Answer: Topiramate. Rationale: FDA pregnancy category X.

• Question Stem: A 30‑year‑old patient on lisdexamfetamine develops tachycardia and hypertension. Which monitoring parameter should be prioritized?
  Answer: Blood pressure and heart rate. Rationale: Stimulants increase sympathetic tone.

Key Differentiators Students Often Confuse

• Fluoxetine vs. Sertraline: Fluoxetine has a longer half‑life and active metabolite, allowing missed doses; sertraline requires strict adherence.

• SSRIs vs. SNRIs: SNRIs (venlafaxine) also increase norepinephrine, providing additional benefit in impulsivity but higher risk of hypertension.

• Topiramate vs. Lisdexamfetamine: Topiramate reduces appetite via GABA/glutamate modulation; lisdexamfetamine reduces bingeing via dopaminergic surge.

Must‑Know Facts

• Fluoxetine is the only FDA‑approved drug for bulimia nervosa.

• Lisdexamfetamine is the first FDA‑approved agent for binge‑eating disorder.

• All stimulants require baseline cardiovascular assessment.

• Serotonin syndrome can arise from combining SSRIs with MAO inhibitors.

• Topiramate is teratogenic; avoid in pregnancy.

Key Takeaways

1. Eating disorders are life‑threatening conditions with distinct neurobiologic substrates.

2. Fluoxetine is the only FDA‑approved pharmacotherapy for bulimia nervosa.

3. Lisdexamfetamine is FDA‑approved for binge‑eating disorder, offering a dose‑responsive reduction in binge episodes.

4. Topiramate, while off‑label, is effective for binge‑eating disorder and weight loss in anorexia nervosa.

5. SSRIs require careful titration and monitoring for serotonin syndrome.

6. Stimulants demand baseline cardiovascular assessment and vigilance for abuse potential.

7. Renal and hepatic impairment necessitate dose adjustments for topiramate, lisdexamfetamine, fluoxetine, and sertraline.

8. Pregnancy considerations: topiramate is teratogenic; fluoxetine and sertraline carry category C risk.

9. Adjunctive antipsychotics can address mood dysregulation but increase metabolic side effects.

10. Multidisciplinary care, combining pharmacotherapy with psychotherapy, remains the cornerstone of treatment.

Clinical reminder: Early identification and comprehensive, individualized treatment plans—combining medication, psychotherapy, and nutritional rehabilitation—are essential for improving survival and quality of life in patients with eating disorders.